8 results
The objectives of this study are to investigate the efficacy and safety of Nilvadipine as a disease course modifying treatment for mild to moderate AD in a phase III double-blind placebo-controlled study. substudy1 (frailty): the objectives of this…
To demonstrate non-inferiority of continuation of platelet inhibiting drugs in eyelid surgery regarding the risk of haemorrhagic complications.
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
Primary objectives:*To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces therisk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with…
The primary objective of the study is to assess the efficacy and safety of 3 different treatment arms (bevacizumab alone, atezolizumab-bevacizumab combination with acetylsalicylic acid and atezolizumab-bevacizumab combination with placebo) in…
To study the effect of 80mg aspirin (given orally once daily for five years) on fiveyear overall survival (OS) for stage II and III colon cancer patients
To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.
To assess whether and to what extent dual therapy clopidogrel 75 mg/acetylsalicylic acid 80 mg daily is superior to monotherapy clopidogrel 75 mg daily, in reducing the combined endpoint all-cause death and cardiovascular adverse events after one-…